Clinical trials
T Cells clinical trials
Below are recruiting t cells clinical trials, each written for real people, not researchers. We’re tracking 5,710 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04969354RecruitingPhase 1
CAIX-targeted CAR-T therapy for advanced kidney cancer
This early-phase study tests a lab-made immune treatment (CAIX-targeted CAR-T cells) for advanced kidney cancer that has not gone away with standard targeted therapy or immunotherapy. If eligible, the goal is to see if the treatment can safely shrink the cancer and improve outcomes.
Xuzhou, JiangsuAges 18–70 - NCT04571203RecruitingPhase 1
Kidney transplant plus blood-cell treatment to help the graft settle
This Phase 1 study tests a treatment plan (including rabbit medicine and a low dose of radiation) meant to help the new kidney “take” and work longer. It also includes a kidney-from-deceased-donor process and checks how safely the treatment works in people with end-stage kidney disease.
Palo Alto, CaliforniaAges 18–65 - NCT04088422Recruiting
Blood test DNA study in mature B-cell lymphoma
This study looks at “cell-free DNA,” meaning tiny bits of DNA found in blood, in people with mature B-cell lymphoma. It may help doctors understand the disease better and how blood tests could be used to monitor it.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04428671RecruitingPhase 1
Cemiplimab before and after surgery for high-risk skin cancer
This Phase 1 trial tests the drug cemiplimab given before and after surgery to reduce the chance that high-risk cutaneous squamous cell cancer comes back. You may be a candidate if your cancer is high-risk on pathology or imaging and is planned for surgical removal.
Atlanta, GeorgiaAges 18 years+ - NCT04661020RecruitingPhase 2
CD19 CAR-T for newly diagnosed high-risk large B-cell lymphoma
This study tests a customized cancer treatment called CD19 CAR-T for people newly diagnosed with certain high-risk large B-cell lymphoma. It aims to see whether this treatment can help control the lymphoma, especially in higher-risk cases.
Hangzhou, ZhejiangAges 18 years+ - NCT05436509RecruitingPhase 1/Phase 2
CD19/79b CAR-T therapy for certain B-cell cancers
This early-phase study tests a one-time engineered immune-cell treatment (CAR-T) made to recognize CD19 and CD79b on certain cancer cells. It may help people with specific B-cell cancers, but you must meet several health and infection-safety requirements to join.
Shenzhen, GuangdongAges 6 months–75 years - NCT03980769RecruitingPhase 2
Stem cell transplant trial for non-cancer blood disorders
This Phase 2 study tests a specific chemotherapy combination (treosulfan, fludarabine, and thiotepa) before an unrelated or matched donor stem cell transplant. It may help people with certain non-cancer blood and immune disorders by trying to reset the immune system using donor stem cells.
Seattle, WashingtonAges Up to 50 years - NCT01189786Recruiting
Stem cell transplant add-on that removes some immune cells
This trial tests a lab-made cell treatment added around an allogeneic stem cell transplant (donor transplant). It tries to improve transplant safety and outcomes by removing certain immune cells from the donor stem cells.
Houston, TexasAges Up to 70 years - NCT03357172Recruiting
Study immune changes after a stem cell transplant
This study looks at how the immune system changes after an allogeneic stem cell transplant (using a donor’s stem cells). It may help researchers understand what controls immune recovery and transplant-related complications.
Vandœuvre-lès-NancyAges 18 years+ - NCT07127289RecruitingPhase 2
Stem cell infusion for low blood counts after CAR-T therapy
This trial tests if giving back your own stored stem cells can help restore low blood cell counts that persist or develop 30 to 90 days after CAR-T therapy for multiple myeloma.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06838832RecruitingPhase 1/Phase 2
New CAR-T cell therapy for relapsed B-cell lymphoma
This trial tests a new treatment made from your own immune cells (gamma-delta T cells) that are engineered to find and kill CD19-positive lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after at least two standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT06249256RecruitingEarly Phase 1
Fast CAR T cells for advanced solid tumors
This trial tests a new type of CAR-T cell therapy called Fast CAR T cells for people with advanced solid tumors. It is designed for patients whose tumors have certain markers (mesothelin and PD-L1) and who have not responded to or cannot tolerate standard treatments.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT03685721Recruiting
Study genes in sickle cell disease to compare blood test activity
This study looks at how a person’s genes relate to certain measurements in red blood cells in people with sickle cell disease. The goal is to understand why blood cell function varies and how that might guide future care.
Bethesda, MarylandAges 18–80 - NCT07179770RecruitingPhase 1
Belzutifan and imaging in advanced kidney cancer
This trial tests a new drug called belzutifan combined with a special imaging agent (89Zr-DFO-girentuximab) to see how they affect PET scans in people with advanced clear cell kidney cancer. It may help doctors better understand the cancer and guide treatment.
New York, New YorkAges 18 years+ - NCT06716619RecruitingPhase 1
Immune cell therapy for advanced solid tumors
This trial tests a new immune cell treatment made from your own lymph nodes for advanced solid tumors that haven't responded to standard therapies or have no good treatment options. It aims to see if this personalized cell therapy is safe and can help shrink tumors.
Guangzhou, GaungdongAges 18–75 - NCT06706102RecruitingPhase 4
Study of Tiny Blood Particles During CAR-T Therapy
This study is for people getting CAR-T cell therapy, a type of cancer treatment that uses your own immune cells. Researchers want to understand a rare side effect called neurotoxicity by looking at tiny particles in your blood called extracellular vesicles.
Saint-EtienneAges 18 years+ - NCT07345728Recruiting
BAFFR CAR-T therapy for relapsed B-cell lymphoma
This trial tests a new CAR-T cell treatment that targets a protein called BAFFR on cancer cells. It is for people with B-cell lymphoma that has come back or not responded to previous treatments.
WuhanAges 18–78 - NCT07444281RecruitingPhase 1
CAR T-cell therapy for GPC3-positive advanced lung cancer
This trial tests a new type of immunotherapy called CAR T-cells (C-CAR031) for people with advanced squamous cell lung cancer that has a specific marker called GPC3. The treatment involves collecting your own immune cells, modifying them to attack cancer, and infusing them back into your body.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05886036RecruitingPhase 2
Comparing rituximab vs mosunetuzumab for NLPHL
This trial compares two immunotherapy drugs, rituximab and mosunetuzumab, to see which works better for people with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) who need treatment. It's for both newly diagnosed and previously treated patients.
Duarte, CaliforniaAges 18 years+ - NCT07702578RecruitingPhase 3
Study of special donor T-cells for blood stem cell transplant
This trial tests whether giving specially engineered donor T-cells after a stem cell transplant can help treat certain blood cancers like AML or MDS. The study is for people receiving a donor stem cell transplant for the first time.
Gilbert, ArizonaAges 18 years+ - NCT04914091Recruiting
Study comfort and medication use after CAR-T therapy
This study looks at quality of life and how medicines are used for people who are getting CAR-T cell therapy for DLBCL. It aims to better understand what helps patients feel and function during follow-up after treatment.
Pierre-BéniteAges 18 years+ - NCT06071871RecruitingPhase 2
A trial of 3 drugs before or after CAR-T for lymphoma
This trial tests a combination of three drugs (polatuzumab vedotin, obinutuzumab, and glofitamab) for people with a type of large B-cell lymphoma. It is given either as a bridge treatment before CAR-T cell therapy or to those who did not fully respond to CAR-T.
LondonAges 18 years+ - NCT07479667RecruitingPhase 1
Targeted immune cell therapy for solid tumors after surgery and chemo
This trial tests a new type of immune cell therapy (dendritic cells) that is designed to target specific proteins found on cancer cells. It is for people with certain solid tumors who have already had surgery and at least 4 cycles of standard chemotherapy after surgery.
ShanghaiAges 18–80 - NCT07692841RecruitingPhase 3
One dose vs two doses of G-CSF for stem cell donors
This trial compares giving a single dose of G-CSF versus splitting it into two doses to see which works better for collecting stem cells from healthy bone marrow donors. The goal is to find a simpler and possibly more comfortable way to help donors produce enough stem cells for transplant.
Changsha, HunanAges 18–65
Hear when a new T Cells trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for t cells?
- Yes. Clin2 currently lists 5,710 recruiting t cells studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a t cells trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a t cells trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.